Products for Research Use Only
RegisterLogin

Allitinib

CAT: 0804-HY-15375-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-15375-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Allitinib (AST-1306) is an orally active and irreversible EGFR and ErbB2 inhibitor with IC50s of 0.5 and 3 nM, respectively. Allitinib also inhibits ErbB4 with an IC50 of 0.8 nM. Allitinib is an anilino-quinazoline compound and has anti-cancer activity[1].
CAS Number
897383-62-9
Product Name Alternative
AST-1306; ALS 1306
UNSPSC
12352005
Hazard Statement
H302, H315, H319
Target
EGFR
Type
Reference compound
Related Pathways
JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/ast-1306.html
Purity
99.36
Solubility
DMSO : 20 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
FC1=CC=CC(COC2=C(Cl)C=C(NC3=NC=NC4=C3C=C(NC(C=C)=O)C=C4)C=C2)=C1
Molecular Formula
C24H18ClFN4O2
Molecular Weight
448.88
Precautions
H302, H315, H319
References & Citations
[1]Xie H, Lin L, Tong L et al. AST1306, a novel irreversible inhibitor of the epidermal growth factor receptor 1 and 2, exhibits antitumor activity both in vitro and in vivo. PLoS One. 2011;6 (7) :e21487.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture and light)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
EGFR/ErbB1/HER1; ErbB2/HER2; ErbB4/HER4
Citation 01
Cell Rep. 2025 Apr 16;44 (5) :115572.|Sci Data. 2024 Sep 19;11 (1) :1024.

Alternative Products

CatalogName
T14336-01Allitinib
A10062-50Allitinib tosylate50mg
T6331-01Allitinib tosylate
A10062-10Allitinib tosylate 10mg
A10062-5Allitinib tosylate 5mg
207119Allitinib free base
A10062-25Allitinib tosylate 25mg

Popular Products